Barclays Maintains Overweight on LifeStance Health Gr, Raises Price Target to $15
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Peter Warendorf maintains LifeStance Health Gr (NASDAQ:LFST) with a Overweight and raises the price target from $13 to $15.
Barclays analyst Peter Warendorf maintains LifeStance Health Gr (NASDAQ:LFST) with a Overweight and raises the price target from $13 to $15.